Status:
NOT_YET_RECRUITING
ALDOA Expression in Bladder Urothelial Carcinoma
Lead Sponsor:
Assiut University
Conditions:
Bladder Urothelial Carcinoma
Eligibility:
All Genders
Brief Summary
1. Study the immunohistochemical expression of ALDOA in bladder urothelial cancer. 2. Correlate between ALDOA expression in specimens and different cilnicopathological factors. 3. Correlate between AL...
Detailed Description
Bladder cancer is the 7th most prevalent malignancy and the 13th cause of cancer related death worldwide1. In Egypt, it's the third most common tumor2. The most common histologic subtype of bladder c...
Eligibility Criteria
Inclusion
- All cases diagnosed as bladder urothelial cancer with known follow-up data and presence of muscle proper detected in the specimens.
Exclusion
- Subtypes of bladder cancer other than urothelial carcinoma subtype.
- Cases of urothelial carcinoma without known follow up data.
- Cases of urothelial carcinoma without muscle proper detected in the specimen.
Key Trial Info
Start Date :
September 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2025
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06550947
Start Date
September 1 2024
End Date
August 1 2025
Last Update
August 13 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.